How to access Enspryng from Saudi Arabia — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient recently diagnosed with neuromyelitis optica spectrum disorder (NMOSD) may receive a prescription for Enspryng (satralizumab-mwge) from their treating neurologist or neuroimmunology specialist. Enspryng is FDA-approved for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, and it is manufactured by Genentech (Roche). It targets the interleukin-6 (IL-6) receptor — a distinct mechanism from anti-CD19 B-cell depletion or terminal complement inhibition, and uniquely among approved NMOSD biologics it is administered subcutaneously, which makes long-term maintenance substantially more home-friendly. In Saudi Arabia, Enspryng may not yet be broadly registered, which is why your neurologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Enspryng is a humanised anti-IL-6 receptor monoclonal antibody administered as a 120 mg subcutaneous injection. The induction schedule is weeks 0, 2, and 4, followed by maintenance every four weeks. Eligibility typically requires confirmed AQP4-IgG seropositivity, a pre-treatment screening bundle (hepatitis B, tuberculosis, liver function, lipid profile, and up-to-date vaccinations), and exclusion of active infection. Your treating neurologist confirms diagnosis and supervises the injection schedule per FDA labeling.
Is Enspryng legally importable into Saudi Arabia?
Yes — through the Saudi Food and Drug Authority (SFDA) named-patient import framework. The pathway allows a Saudi-licensed physician to request import of a medicine not broadly registered locally when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented through a licensed importing entity.
For Enspryng specifically, the application benefits from the subcutaneous administration route — there is no infusion-centre bottleneck, though the first dose is typically administered or observed in a clinical setting. Maintenance doses can be given at home by a trained patient or caregiver.
How the pathway works, step by step
- Consultation with your treating neurologist. AQP4-IgG confirmation, NMOSD clinical diagnosis, and pre-treatment screening (hepatitis B, TB, LFTs, lipid panel, vaccinations).
- SFDA named-patient application. Your physician files the application including clinical letter, patient identifier, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure the product from the manufacturer's authorised distribution chain.
- Cold-chain shipment. Enspryng ships at 2–8°C with continuous temperature monitoring.
- Arrival and administration. The treating centre administers or observes the first dose; subsequent doses may be home-administered under physician supervision.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming NMOSD diagnosis and AQP4-IgG seropositivity with supporting MRI and clinical evidence
- Verification of Saudi medical licence
- Patient identifier
- Pre-treatment screening results (hepatitis B, TB, LFTs, lipid panel, vaccination record)
- Planned induction (weeks 0, 2, 4) and four-weekly maintenance schedule
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for NMOSD monoclonal-antibody therapy.
Costs and timing
Enspryng's US cash-pay reference price sits in a broad indicative range — the annualised treatment cost sits in the USD 200,000–300,000 range in US list pricing, depending on dosing frequency after the loading period. International cold-chain logistics, SFDA documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for the first dose after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted. Screening lead time may extend this.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Enspryng specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for SFDA review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation.
How does Enspryng compare with Uplizna or Soliris for NMOSD? All three are FDA-approved for AQP4-IgG-positive NMOSD. Enspryng blocks IL-6R (subcutaneous, q4-weeks after loading); Uplizna depletes CD19 B cells (IV, q6-months); Soliris inhibits terminal complement (IV, q2-weeks). Enspryng's subcutaneous route is often preferred for long-term maintenance in patients who prefer home administration. Your neurologist chooses based on disease severity, infusion logistics, and comorbidities.
Can I inject at home? After the first dose is administered or supervised in a clinical setting and your neurologist is satisfied with technique, most patients can self-inject or have a caregiver inject at home.
Will private insurance cover this? Cash-pay is the default. Some Saudi private insurers reimburse NMOSD therapy on escalated review; we supply documentation but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Enspryng coordination in Saudi Arabia.
Add me to the Enspryng waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.